Molecule
Nogapendekin alfa inbakicept is an interleukin-15 receptor agonist indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). It is available as injection for intravesical use. MedsAcross supplies Nogapendekin alfa inbakicept for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).
Source: US FDA prescribing information
Nogapendekin alfa inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4 + and CD8 + T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8 +, and memory T cells without proliferation of immuno-suppressive Treg cells. In vivo, intravesicular nogapendekin alfa inbakicept-pmln alone or in combination with BCG showed anti-tumor activity when compared to BCG alone, in a carcinogen-induced model of bladder cancer in immunocompetent rats.
Source: US FDA prescribing information
For Intravesical Use Only For induction: 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if patients have residual carcinoma in situ (CIS) and/or high-grade Ta tumors at month 3. For maintenance: 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19. For patients with no evidence of high-grade disease at month 25 and later, additional maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. See full Prescribing Information for dilution and administration instructions.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
Delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal. Risk of Metastatic Bladder Cancer with Delayed Cystectomy Delaying cystectomy in patients with BCG-unresponsive NMIBC could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting BCG-unresponsive NMIBC. Of the 77 evaluable patients with BCG-unresponsive CIS treated with ANKTIVA with TICE BCG in QUILT-3.032, 10% (n = 8) progressed to muscle invasive (T2 or greater) bladder cancer, including 7 during the treatment period. Three patients had progression determined at the time of cystectomy.
Source: US FDA prescribing information
The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.
Source: US FDA prescribing information
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Nogapendekin alfa inbakicept, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Anktiva 400 mcg/0.4 mL injectionIntravesical Cold chain | Altor BioScience, LLC, an indirect wholly-owned | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Nogapendekin alfa inbakicept and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Nogapendekin alfa inbakicept, including Anktiva.
Yes. The US FDA first approved Nogapendekin alfa inbakicept on 22 April 2024, according to Drugs@FDA.
Yes. Nogapendekin alfa inbakicept has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Nogapendekin alfa inbakicept must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Nogapendekin alfa inbakicept is classified under ATC code L03AC03 (Nogapendekin alfa inbakicept).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.